Navin Fluorine International Ltd (NAVINFLUOR) Growth Catalysts - Q1 FY27 (Jun-26)
10 growth catalysts flagged by management, 4 new in the recent quarters, 2 no longer discussed.
Reported base: Rev INR1,045 cr (+44% YoY), Operating EBITDA INR357 cr (+73% YoY, margin 34.2%), PAT INR243 cr (+108% YoY); turned net debt free, OCF INR173 cr, NWC at 81 days.
Growth catalysts
European CDMO scale-up deliveries
Mgmt is scaling commercial execution across late-stage molecules and newly commissioned cGMP-4 capacity to achieve a $100M CDMO revenue run-rate target in FY27. CDMO commercial scale-up deliveries scheduled for execution.
Quantum: Q4 FY26 deliveries; $100 million target · Timeline: FY27 · CDMO · Customer/contract
Discussed on the earnings calls of Jun-26, Mar-26, Dec-25.
CDMO cGMP4 Phase 2 Capex
Mgmt initiated Phase 2 cGMP4 capex of INR 125 cr funded via internal accruals to supply an additional molecule (API minus 1). Completion is scheduled for Q4 FY27, targeting a 3x asset turn on total INR 288 cr cGMP4 capex by FY29.
Quantum: INR 125 cr · Timeline: Q4 FY27 · CDMO · Capacity
Discussed on the earnings calls of Jun-26.
8 more growth catalysts on the Stocksigma ELITE plan.
Guidance & timelines
- CDMO Annual Revenue Target: Targeting $100M revenue run-rate on track (Timeline: FY27)
- Consolidated EBITDA Margin Range: Normalized consolidated EBITDA margin expected around 32%-33% (+/- 100 bps) (Timeline: Next 1-2 years)
9 more guidance items on ELITE.